Publications by authors named "E Bignotti"
Objective: The prognostic relevance of hormonal biomarkers in endometrial cancer (EC) has been well-established. A refined three-tiered risk model for estrogen receptor (ER)/progesterone receptor (PR) expression was shown to improve prognostication. This has not been evaluated in relation to the molecular subgroups.
View Article and Find Full Text PDFArticle Synopsis
- In ovarian cancer, a comprehensive study examined various metabolism-related markers to understand their prognostic value, but results showed mixed outcomes in large patient groups.
- The study used advanced techniques on tissue samples from over 300 patients to analyze markers tied to glycolysis, glutamine metabolism, and hypoxia, but found that only one marker (GLS) hinted at a connection to patient survival, which was not statistically significant after adjustments.
- Ultimately, the research highlights the diversity of metabolism markers in ovarian cancer and suggests their expression patterns may still be relevant for future drug development, even if they don't currently correlate with treatment outcomes.
Background/objectives: Endometriosis (END) is a painful gynecological condition. Clinical examination, imaging, and laparoscopy can provide a definitive diagnosis of END. Nonetheless, non-invasive biomarkers could help enhance and streamline the diagnostic process.
View Article and Find Full Text PDFArticle Synopsis
- There are currently no specific biomarkers to identify patients with advanced ovarian carcinoma who are responsive to bevacizumab (BEV), a key treatment option.
- A study analyzed TP53 mutations and p53 expression in advanced ovarian cancer patients undergoing BEV treatment, finding that unclassified missense TP53 mutations significantly improved overall survival.
- The results suggest that unclassified TP53 mutations could serve as a favorable prognostic indicator in these patients, indicating the need for further research to explore their potential role in predicting treatment outcomes.
Background: Response to hormonal therapy in advanced and recurrent endometrial cancer (EC) can be predicted by oestrogen and progesterone receptor immunohistochemical (ER/PR-IHC) expression, with response rates of 60% in PR-IHC > 50% cases. ER/PR-IHC can vary by tumour location and is frequently lost with tumour progression. Therefore, we explored the relationship between ER/PR-IHC expression and tumour location in EC.
View Article and Find Full Text PDF